Trial Profile
A comparative study of tolterodine and diltiazem effects on OAB after prostatectomy.
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 14 Sep 2016
Price :
$35
*
At a glance
- Drugs Diltiazem (Primary) ; Tolterodine (Primary)
- Indications Overactive bladder
- Focus Therapeutic Use
- 04 Jul 2012 Status changed from recruiting to active, no longer recruiting as reported by Iranian Registry of Clinical Trials.
- 05 Oct 2011 New trial record